ETS1 and breast cancer: Intriguingly, we found that BRCA patients in the ETS1low group were significantly more likely to have a poor prognosis in TCGA (P = 0.0165) as well as the Curtis (P = 0.0076) database (Figure 1C and Supplementary Figures 1A,B), compared to BRCA patients in ETS1high group not in triple-negative type specific manners (Supplementary Figures 1C,D) suggesting the potential of ETS1 as the anti-tumorigenic factor in breast cancer.